UVA spin-off company spurs first-in-human trial of therapy for sepsis-induced acute respiratory distress syndrome
A scientific discovery aimed at stopping dangerous immune-system overreactions could soon offer hope to patients facing sepsis, ARDS, or other forms of inflammation.